Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oncological resource allocation in Germany.

Michael Hartmann1, Roland Kath, Christin Gundermann

  • 1Faculty of Medicine, Friedrich-Schiller-University of Jena, Germany. Michael.Hartmann@med.uni-jena.de

Onkologie
|March 7, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Variability and Predictors of Isotretinoin Dosing in Acne Patients: A Retrospective Cohort Study.

Clinical and experimental dermatology·2026
Same author

Health economic evaluation of Mirvetuximab soravtansine for the treatment of FRα-positive, platinum resistant ovarian cancer in Germany.

Journal of cancer research and clinical oncology·2026
Same author

Leveraging mixed-mode filter during cell culture harvest to prevent antibody reduction.

Journal of biotechnology·2026
Same author

Biocatalytic cascades enable manufacture of the macrocyclic peptide enlicitide.

Science (New York, N.Y.)·2026
Same author

Blood Culture Contamination and Subsequent Unnecessary Health Care Utilization in Pediatrics.

Hospital pediatrics·2026
Same author

Phage Display-Based Discovery of HPV Capsomere-Specific Antibodies for HPV Process Characterization.

Biotechnology journal·2026
Same journal

Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma.

Onkologie·2013
Same journal

Metastatic germ cell tumour following renal transplantation.

Onkologie·2013
Same journal

miR-145 inhibits proliferation and invasion of esophageal squamous cell carcinoma in part by targeting c-Myc.

Onkologie·2013
Same journal

A meta-analysis of internal mammary lymph node metastasis in breast cancer patients.

Onkologie·2013
Same journal

Patient-related delay in presentation for cutaneous squamous cell carcinoma. A cross-sectional clinical study.

Onkologie·2013
Same journal

Treatment of primary breast cancer at the surgical unit of the Charité 1984-1998.

Onkologie·2013
See all related articles

Oncology in Germany is resource-intensive, with higher costs per year of life gained compared to other diseases. Significant variations in efficiency exist within cancer treatments.

Area of Science:

  • Health Economics
  • Oncology
  • Public Health Policy

Background:

  • Oncology is a high-cost medical field where treatment effectiveness has historically overshadowed efficiency.
  • Understanding resource allocation and efficiency in oncology is crucial for healthcare system sustainability.

Purpose of the Study:

  • To determine resource allocation in German oncology from 2002-2004.
  • To assess the efficiency of oncology treatments in Germany during the study period.

Main Methods:

  • Analysis of the official German Health Report for expenditures and life years gained by ICD 10 disease categories in 2004.
  • Calculation of cost per year of life gained using incremental costs and life years.

Main Results:

Related Experiment Videos

  • Malignant neoplasms accounted for 15 billion Euros in health expenditures, ranking 5th.
  • The cost per year of life gained for malignant neoplasms was 140,750 Euros, exceeding that of respiratory, digestive diseases, and injuries.
  • Costs per year of life gained for specific cancers varied widely, from 39,000 Euros for lip/oral cavity/pharynx cancers to 126,000 Euros for digestive organ cancers.

    • Conclusions:

    • Oncology in Germany demonstrates higher costs per year of life gained compared to several other disease categories.
    • Substantial differences in resource allocation and efficiency are evident within malignant neoplasms.